Shu Fen Wen

1.5k total citations
18 papers, 1.3k citations indexed

About

Shu Fen Wen is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Shu Fen Wen has authored 18 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 12 papers in Genetics and 9 papers in Oncology. Recurrent topics in Shu Fen Wen's work include Virus-based gene therapy research (11 papers), Cancer Research and Treatments (6 papers) and Cancer-related Molecular Pathways (6 papers). Shu Fen Wen is often cited by papers focused on Virus-based gene therapy research (11 papers), Cancer Research and Treatments (6 papers) and Cancer-related Molecular Pathways (6 papers). Shu Fen Wen collaborates with scholars based in United States, China and Germany. Shu Fen Wen's co-authors include Suxing Liu, Loretta L. Nielsen, Paul T. Kirschmeier, Luquan Wang, Cecil B. Pickett, W. Robert Bishop, Asra Mirza, Qun Wu, Hena R. Ashar and Stuart Black and has published in prestigious journals such as Journal of Clinical Oncology, Oncogene and Journal of Virology.

In The Last Decade

Shu Fen Wen

18 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shu Fen Wen United States 15 857 626 466 258 132 18 1.3k
Timothy K. MacLachlan United States 22 1.2k 1.4× 552 0.9× 356 0.8× 81 0.3× 145 1.1× 46 1.6k
Shumpei Ohnami Japan 20 397 0.5× 411 0.7× 264 0.6× 92 0.4× 137 1.0× 53 967
Holly Symonds United States 9 729 0.9× 741 1.2× 161 0.3× 212 0.8× 104 0.8× 9 1.1k
Sétha Douc‐Rasy France 20 987 1.2× 528 0.8× 128 0.3× 115 0.4× 61 0.5× 38 1.4k
Scott Bader United States 19 1.2k 1.3× 456 0.7× 314 0.7× 73 0.3× 78 0.6× 28 1.7k
A Kasid United States 18 686 0.8× 639 1.0× 577 1.2× 112 0.4× 608 4.6× 23 1.5k
Nianjun Tao United States 8 539 0.6× 377 0.6× 394 0.8× 48 0.2× 133 1.0× 12 1.1k
Dell Paielli United States 12 1.2k 1.4× 744 1.2× 1.2k 2.6× 349 1.4× 103 0.8× 13 1.8k
Didier Jean France 25 781 0.9× 441 0.7× 95 0.2× 160 0.6× 227 1.7× 50 1.7k
Ta-Jen Liu United States 14 620 0.7× 373 0.6× 234 0.5× 191 0.7× 28 0.2× 20 894

Countries citing papers authored by Shu Fen Wen

Since Specialization
Citations

This map shows the geographic impact of Shu Fen Wen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shu Fen Wen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shu Fen Wen more than expected).

Fields of papers citing papers by Shu Fen Wen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shu Fen Wen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shu Fen Wen. The network helps show where Shu Fen Wen may publish in the future.

Co-authorship network of co-authors of Shu Fen Wen

This figure shows the co-authorship network connecting the top 25 collaborators of Shu Fen Wen. A scholar is included among the top collaborators of Shu Fen Wen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shu Fen Wen. Shu Fen Wen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Chen, Lei, Jianchun Li, Xiang‐Hong Ou, et al.. (2012). Defective Histone H3K27 Trimethylation Modification in Embryos Derived from Heated Mouse Sperm. Microscopy and Microanalysis. 18(3). 476–482. 6 indexed citations
2.
Wen, Shu Fen, Hong Li, Mo‐Li Wu, et al.. (2010). Inhibition of NF-κB signaling commits resveratrol-treated medulloblastoma cells to apoptosis without neuronal differentiation. Journal of Neuro-Oncology. 104(1). 169–177. 18 indexed citations
3.
Wen, Shu Fen, Hong Li, & Jia Liu. (2009). Dynamic signaling for neural stem cell fate determination. Cell Adhesion & Migration. 3(1). 107–117. 45 indexed citations
4.
Wen, Shu Fen, Hong Li, & Jia Liu. (2008). Epigenetic background of neuronal fate determination. Progress in Neurobiology. 87(2). 98–117. 21 indexed citations
5.
Zhang, Peng, Hong Li, Mo‐Li Wu, et al.. (2006). c-Myc downregulation: a critical molecular event in resveratrol-induced cell cycle arrest and apoptosis of human medulloblastoma cells. Journal of Neuro-Oncology. 80(2). 123–131. 50 indexed citations
6.
Machemer, Todd, Heidrun Engler, Van Tsai, et al.. (2005). Characterization of Hemodynamic Events Following Intravascular Infusion of Recombinant Adenovirus Reveals Possible Solutions for Mitigating Cardiovascular Responses. Molecular Therapy. 12(2). 254–263. 13 indexed citations
7.
Tsai, Van, Duane E. Johnson, Amena Rahman, et al.. (2004). Impact of Human Neutralizing Antibodies on Antitumor Efficacy of an Oncolytic Adenovirus in a Murine Model. Clinical Cancer Research. 10(21). 7199–7206. 69 indexed citations
8.
Wen, Shu Fen, Erlinda Quijano, Michael J. Grace, et al.. (2003). Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Therapy. 10(3). 224–238. 35 indexed citations
9.
Mirza, Asra, Qun Wu, Hena R. Ashar, et al.. (2002). Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene. 21(17). 2613–2622. 462 indexed citations
10.
Kuball, Jürgen, Shu Fen Wen, J. Leißner, et al.. (2002). Successful Adenovirus-Mediated Wild-Type p53 Gene Transfer in Patients With Bladder Cancer by Intravesical Vector Instillation. Journal of Clinical Oncology. 20(4). 957–965. 105 indexed citations
11.
Wills, Ken N., Isabella Atencio, Jenny B. Avanzini, et al.. (2001). Intratumoral Spread and Increased Efficacy of a p53-VP22 Fusion Protein Expressed by a Recombinant Adenovirus. Journal of Virology. 75(18). 8733–8741. 44 indexed citations
12.
Rahman, Amena, Van Tsai, Shu Fen Wen, et al.. (2001). Specific Depletion of Human Anti-adenovirus Antibodies Facilitates Transduction in an in Vivo Model for Systemic Gene Therapy. Molecular Therapy. 3(5). 768–778. 41 indexed citations
13.
Hirai, Manabu, Drake LaFace, Simon N. Robinson, et al.. (2001). Ex vivo purging by adenoviral p53 gene therapy does not affect NOD-SCID repopulating activity of human CD34+ cells. Cancer Gene Therapy. 8(12). 936–947. 6 indexed citations
14.
Wen, Shu Fen, Lei Xie, Maya Gurnani, et al.. (2000). Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models. Cancer Gene Therapy. 7(11). 1469–1480. 28 indexed citations
15.
Anderson, Scott, Duane E. Johnson, Matthew P. Harris, et al.. (1998). p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus.. PubMed. 4(7). 1649–59. 79 indexed citations
16.
Geradts, Joseph, et al.. (1996). Wild-type and mutant retinoblastoma protein in paraffin sections.. PubMed. 9(3). 339–47. 43 indexed citations
17.
Wills, Ken N., Daniel C. Maneval, Patricia Menzel, et al.. (1994). Development and Characterization of Recombinant Adenoviruses Encoding Human p53 for Gene Therapy of Cancer. Human Gene Therapy. 5(9). 1079–1088. 204 indexed citations
18.
Wen, Shu Fen, et al.. (1994). Retinoblastoma protein monoclonal antibodies with novel characteristics. Journal of Immunological Methods. 169(2). 231–240. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Timothy K. MacLachlan Breakdown of academic impact, for papers by Shumpei Ohnami Breakdown of academic impact, for papers by Holly Symonds Breakdown of academic impact, for papers by Sétha Douc‐Rasy Breakdown of academic impact, for papers by Scott Bader Breakdown of academic impact, for papers by A Kasid Breakdown of academic impact, for papers by Nianjun Tao Breakdown of academic impact, for papers by Dell Paielli Breakdown of academic impact, for papers by Didier Jean Breakdown of academic impact, for papers by Ta-Jen Liu
Rankless by CCL
2026